Table 1:

Demographics and characteristics of study patients.

	Head and Neck Cancer (n=56)	Lung Cancer (n=6)	Pancreatic Cancer (n=11)	Brain Cancer (n=8)	Totals (n=81)
Age, years (range)	61 (32–85)	60 (32–71)	66 (40–82)	59 (42–72)	61 (32–85)
Female (%)	19 (33.9%)	4 (66.7%)	1 (9.1%)	5 (62.5%)	29 (35.8%)
Weight, kg (range)	73 (41–101)	82 (52–138)	75 (62–101)	73 (41–91)	74 (41–138)
Tumor staging
Stage 1	5 (8.9%)	-	1 (9.1%)	-	6 (7.4%)
Stage 2	11 (19.6%)	4 (66.7%)	3 (27.3%)	-	18 (22.2%)
Stage 3	12 (21.4%)	1 (16.7%)	5 (45.5%)	1 (12.5%)	19 (23.5%)
Stage 4	25 (42.8%)	-	2 (18.2%)	7 (87.5%)	34 (41.9%)
Stage unknown	3 (5.3%)	1 (16.7%)	-	-	4 (4.9%)
Prior chemotherapy	4 (7.1%)	1 (16.7%)	5 (45.5%)	2 (25%)	12 (14.8%)
Prior radiation	14 (25%)	1 (16.7%)	2 (18.2%)	2 (25%)	19 (23.5%)
Average antibodya dose, mg/kg (range)	0.9 (0.06–2.4)	0.7 (0.4 –1.1)	2.0 (1.5–2.8)	1.1 (0.6–1.7)	1.1 (0.06–2.8)
Average antibody-dye conjugate dose, mg/kg (range)	0.7 (0.06–1.2)	0.7 (0.4–1.1)	0.7 (0.3–1.2)	1 (0.6–1.4)	0.7 (0.06–1.4)

^aIncludes loading dose.